HUTCHMED (NASDAQ:HCM) Upgraded at StockNews.com

StockNews.com upgraded shares of HUTCHMED (NASDAQ:HCM) from a hold rating to a buy rating in a report issued on Friday morning.

HUTCHMED Stock Down 7.1 %

Shares of NASDAQ HCM opened at $14.99 on Friday. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.68 and a current ratio of 2.81. The business has a fifty day simple moving average of $14.69 and a 200 day simple moving average of $16.49. HUTCHMED has a one year low of $12.84 and a one year high of $21.92.

Hedge Funds Weigh In On HUTCHMED

Several hedge funds have recently added to or reduced their stakes in HCM. Public Employees Retirement System of Ohio bought a new position in HUTCHMED during the third quarter worth about $35,000. Barclays PLC grew its stake in HUTCHMED by 1,483.6% in the fourth quarter. Barclays PLC now owns 2,407 shares of the company’s stock valued at $35,000 after purchasing an additional 2,255 shares in the last quarter. Blue Trust Inc. grew its stake in HUTCHMED by 99.9% in the fourth quarter. Blue Trust Inc. now owns 7,068 shares of the company’s stock valued at $102,000 after purchasing an additional 3,532 shares in the last quarter. Summit Trail Advisors LLC boosted its stake in shares of HUTCHMED by 14.4% during the 4th quarter. Summit Trail Advisors LLC now owns 13,090 shares of the company’s stock worth $189,000 after acquiring an additional 1,647 shares during the period. Finally, OLD Mission Capital LLC bought a new position in shares of HUTCHMED during the 4th quarter worth approximately $230,000. Institutional investors own 8.82% of the company’s stock.

About HUTCHMED

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.